Latest News
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
Business Wire - Thu Nov 7, 9:05AM CST
Business Wire
Thu Nov 7, 9:05AM CST
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
Motley Fool - Mon Nov 4, 10:00PM CST
Motley Fool
Mon Nov 4, 10:00PM CST
ABCL earnings call for the period ending September 30, 2024.
AbCellera Reports Q3 2024 Business Results
Business Wire - Mon Nov 4, 3:05PM CST
Business Wire
Mon Nov 4, 3:05PM CST
AbCellera to Present at Upcoming Investor Conferences in November 2024
Business Wire - Tue Oct 22, 3:05PM CDT
Business Wire
Tue Oct 22, 3:05PM CDT
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
Business Wire - Fri Oct 4, 8:00AM CDT
Business Wire
Fri Oct 4, 8:00AM CDT
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
Business Wire - Thu Sep 26, 3:05PM CDT
Business Wire
Thu Sep 26, 3:05PM CDT
Should You Follow Insider Buying on This Biotech Penny Stock?
Barchart - Sun Sep 8, 10:15AM CDT
Barchart
Sun Sep 8, 10:15AM CDT
With significant insider purchases and high-profile hedge fund interest, AbCellera is one penny stock to watch.
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript
Motley Fool - Tue Aug 6, 11:45PM CDT
Motley Fool
Tue Aug 6, 11:45PM CDT
ABCL earnings call for the period ending June 30, 2024.
1 Billionaire-Backed Penny Stock With 421% Upside
Barchart - Tue Aug 6, 7:43AM CDT
Barchart
Tue Aug 6, 7:43AM CDT
Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Motley Fool - Sun Jul 21, 4:37AM CDT
Motley Fool
Sun Jul 21, 4:37AM CDT
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Motley Fool - Thu Jun 13, 4:40AM CDT
Motley Fool
Thu Jun 13, 4:40AM CDT
Wall Street analysts say this drug developer can more than double your money.
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
Motley Fool - Wed May 8, 3:30AM CDT
Motley Fool
Wed May 8, 3:30AM CDT
ABCL earnings call for the period ending March 31, 2024.
3 AI-Driven Drug Stocks to Buy Before They Breakout
Barchart - Thu Feb 29, 4:41PM CST
Barchart
Thu Feb 29, 4:41PM CST
The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven R&D.
Short sales on the TSX: What bearish investors are betting against
The Globe and Mail - Mon Feb 26, 10:36AM CST
The Globe and Mail
Mon Feb 26, 10:36AM CST
A luxury clothing company continues to be the biggest target
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript
Motley Fool - Tue Feb 20, 10:00PM CST
Motley Fool
Tue Feb 20, 10:00PM CST
ABCL earnings call for the period ending December 31, 2023.
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
Motley Fool - Tue Jan 16, 9:30AM CST
Motley Fool
Tue Jan 16, 9:30AM CST
Healthcare stocks have underperformed in 2023, but that is expected to change this year.
3 Growth Stocks That Could Go Parabolic in 2024
Motley Fool - Mon Jan 15, 8:30AM CST
Motley Fool
Mon Jan 15, 8:30AM CST
These innovation-oriented companies could take flight this year.
AbCellera cuts 10 per cent of staff as biotech slump hits Vancouver antibody developer
The Globe and Mail - Wed Nov 29, 2023
The Globe and Mail
Wed Nov 29, 2023
Company still in โfantasticโ financial condition with more than US$1-billion in liquidity: CEO
Cutting-edge antibody therapy firm AbCellera to lay off 10% of work force
SYNDTGAM - Wed Nov 29, 2023
SYNDTGAM
Wed Nov 29, 2023
A filing to the U.S. SEC said the layoffs and reorganization will help AbCellera โfocus its efforts toward the clinical development of new antibody medicines for patientsโ
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript
Motley Fool - Fri Nov 3, 2023
Motley Fool
Fri Nov 3, 2023
ABCL earnings call for the period ending September 30, 2023.
Argenx's 28% Surge & Promising Product Propel Investor Confidence
MarketBeat - Mon Sep 25, 2023
MarketBeat
Mon Sep 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript
Motley Fool - Fri Aug 4, 2023
Motley Fool
Fri Aug 4, 2023
ABCL earnings call for the period ending June 30, 2023.
AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript
Motley Fool - Thu May 4, 2023
Motley Fool
Thu May 4, 2023
ABCL earnings call for the period ending March 31, 2023.
AbCellera Reports Q1 2023 Business Results
Business Wire - Thu May 4, 2023
Business Wire
Thu May 4, 2023
AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies
Motley Fool - Fri Apr 28, 2023
Motley Fool
Fri Apr 28, 2023
Check out these compelling opportunities.